Efficacy of Glucagon-Like Peptide-1 and Estrogen Dual Agonist in Pancreatic Islets Protection and Pre-clinical Models of Insulin-Deficient Diabetes

Scientists studied the efficacy of a glucagon-like peptide-1 (GLP-1) and estrogen dual agonist (GLP1-E2) in pancreatic islet protection. GLP1-E2 provided superior protection from insulin-deficient diabetes induced by multiple low-dose streptozotocin and by the Akita mutation in mice than a GLP-1 monoagonist.